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Abstract
Background: Few studies have investigated the use of dexmedetomidine in patient-controlled intravenous
analgesia (PCIA) after thoracic surgery. This study to evaluate the effect of dexmedetomidine combined with
sufentanil for PCIA after thoracotomy under general anaesthesia.
Methods: Ninety-seven adults patients scheduled for thoracotomy surgery. All two groups received PCIA with
either sufentanil alone (control group) or combining dexmedetomidine with sufentanil (dexmedetomidine group).
Hemodynamic measurements, visual analog scale (VAS) scores at rest and at coughing, Ramsay sedation score (RSS)
, analgesic consumption, and postoperative nausea and vomiting (PONV) as well as drug-related adverse effects
were compared at 2, 6, 12, 24, 36 and 48 h postoperatively.
Results: In the patients of the dexmedetomidine group, compared to the control group, the pain scores at rest or
at coughing during 48 h postoperatively were lower (P < 0.001), the sedation scores were lower, the consumption
of sufentanil and rescue meperidine were lower, and the number of episode of moderate PONV was three times
lower. No signs of toxicity or local complications were observed. There was a non-significant trend for a lower HR
and BP in the dexmedetomidine group vs. Control.
Conclusion: The combining dexmedetomidine with sufentanil for post-thoracotomy PCIA can improve pain control
together with the decrease in sufentanil requirements, and improve postoperative patient’s satisfaction compared
with sufentanil alone in PCIA.
Trial Registration: This trial was retrospectively registered on 27 April 2016 at the Chinese Clinical Trial Register
(number: ChiCTR-ONC-16008376).
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Background
Patients undergoing thoracic surgery experience severe
pain and to have supreme effect on painful respiratory
movements in the postoperative period, in whom it is
reflected by the long duration of patient-controlled anal-
gesia (PCA), compromised pulmonary function can
occur when uncertain analgesia, and high morphine
consumption [1, 2]. The use of morphine is associated
with side effects, which the most important side effects
include nausea, vomiting, sedation and respiratory de-
pression during acute morphine therapy [3]. Therefore,
one of the most promising interventions requiring inves-
tigation is the reduction of postoperative opioid con-
sumption and pain intensity by an adjunct drugs with an
opioid, such as α2-adrenoceptor agonists.
Some studies report that perioperative and postopera-
tive systemic usage of dexmedetomidine provides con-
siderably more satisfactory analgesic effect, reduces PCA
morphine requirements and lower incidence of postop-
erative side effects compared to morphine alone [4–6].
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Compared with morphine, sufentanil improve immediate
postoperative pain control with a strong analgesic effect;
however, because patients undergoing complex thoracot-
omy may be continue to experience respiratory depression
and increase the incidence of other complications, an ad-
junct drug such as dexmedetomidine, has been suggested
as a safe alternative to together with sufentanil by way of
patient-controlled intravenous analgesia (PCIA) [7]. How-
ever, the beneficial properties of dexmedetomidine has been
described as involving analgesia, anxiolysis, sedation and
sympatholysis, the neural networks involving the peripheral
and central mechanisms has been hypothesized to play a
major role in determining less likelihood of adverse-effect
profile and opioid-sparing effect during patient-controlled
intravenous analgesia (PCIA) [8–10].
Our goal was to compare the pain intensity, analgesics
consumption, hemodynamic and the drug-related adverse
effect of PCIA with combining dexmedetomidine with
sufentanil or sufentanil alone protocol in a prospective
randomized study design after thoracotomy operations.
Methods
Ethics approval and consent to participate
This randomized, double-blind, and single-centre study
enrolled sixty-five patients from April 2014 to June
2015. The study was approved by the ethics committee
of the third affiliated hospital of AnHui Medical Univer-
sity for human studies (Ethical Committee number
HFYY2014002) on January 2014, and written informed
consent was obtained from all patients (Chinese Clinical
Trial number, ChiCTR-ONC-16008376). This study
protocol complied with the 1975 Declaration of
Helsinki.
Criteria for inclusion and exclusion
Patients who were classified as American Society of Anes-
thesiologists (ASA) physical status I to II, aged between
32–65 years and scheduled to undergo elective major open
thoracotomy operation under general anesthesia were re-
cruited. Patients were excluded with a serious central ner-
vous system pathology, a left ventricular ejection fraction of
<35%, greater than first-degree atrioventricular block and
rate-controlled atrial fibrillation, acute or chronic hepatitis,
a requirement for renal supplementation, a known uncon-
trolled seizure disorder, use of psychiatric medications, drug
abuse other than alcohol, or cognitive impairment or if they
were pregnant or lactating.
Preoperative preparations and anesthesia protocol
Prior to enrollment, patients were screened for study eli-
gibility. Besides, the patients who refused to fill out the
informed consent was excluded from study. A resident
of anesthetist visited the patients before the operation
and described the visual analogue scale (VAS) for them.
Meanwhile, he prescribed the premedication and 8 h nil-
per-os for the patients. All of the patients were anesthe-
tized by an anesthetist who was blinded to study and
didn’t participate in data collection. Furthermore, the
anesthetist resident who collected post-operative data
were blinded to study and this process continued to end
of the study. All the patients were fully informed about
the study and blinded to their groups. Before surgery,
patients were instructed on the operational use of PCIA
bump and a 0–10 VAS measurements of pain.
All patients were pre-medicated with midazolam
0.05 mg.kg−1 was IV injected 2 h before surgery and re-
ceived IV 500 ml of acetate Ringer’s sodium over 30 min
before induction of anesthesia. Upon arrival in operating
room usual monitoring [including ECG, pulse oxygen
saturation (SpO2), noninvasive blood pressure (BP)] was
established, and the hemodynamic measurements in the
operating room were recorded as a preoperative baseline
values. Narcotrend monitor (Narcotrend index: NI) were
applied before the induction of anesthesia in order to
obtain the anesthesia depth levels. All patients received
0.4 μg.kg−1 sufentanil (sufentanil Citrate; Inc., RenFu
Pharmaceutical, China), and propofol, sevoflurane and
cisatracurium for induction and tracheal intubation, and
then maintenance of anesthesia with a target concentra-
tion infusion of sufentanil (effect-site concentration)
1.0 μg.kg−1.h−1 for intra-operative analgesia, followed by
maintenance with propofol, sevoflurane, oxygen, and
cisatracurium. Intra-operation, a variable concentration
infusion regimen of propofol and sevoflurane were ad-
justed as necessary to maintain an NI values between 40
to 50 as well as haemodynamic responses to surgical
stimuli. Edrophonium and atropine were given to re-
verse residual neuromuscular block at the end of sur-
gery. Patients emerged from the operating room
extubated and total recovery from anesthesia with stayed
1 h in the post anesthetic care unit (PACU) (as judged
by the ability to obey verbal commands on request and
stable hemodynamic variables). All patients were at-
tached to an electronic infusion pump (JA5806 PCA;
Inc., ShangHai ANGEL, ED, China) for PCIA and being
fully awake allowed to back the general ward. The study
commenced in the postoperative period.
Postoperative PCIA strategy
A standard sufentanil in PCIA protocol was adopted
throughout the studied period. According to the
randomization plan, the PCIA regimen consisted of
sufentanil 3.0 μg.kg−1 and 8 mg ondansetron, mixed with
0.9% normal saline to a total volume of 250 ml. In the
dexmedetomidine group, in addition to the sufentanil
and ondansetron, 4.0 μg.kg−1 of dexmedetomidine (Pre-
cedex; Aibeinin®, Inc., Henrui Pharmaceutical, China)
was added to the PCIA solution and again the volume
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was made up to 250 ml with 0.9% normal saline. The
PCIA was programmed to deliver a 2 ml bolus on-
demand, with a lock-out interval of 10 min, and a back-
ground infusion rate of 4 ml.h−1. All patients received
20 ml i.v. of PCIA solution immediately after were at-
tached a PCIA pump. During the study period after sur-
gery, this PCIA programme thus allowed a continuous
background infusion of sufentanil 0.048 μg.kg−1.h−1 and a
bolus of sufentanil 0.024 μg.kg−1; and allowed a continu-
ous background infusion of dexmedetomidine 0.064 μg.kg
−1.h−1 and a bolus of dexmedetomidine 0.032 μg.kg−1. The
PCIA was used for the first 48 h postoperatively. Upon ar-
rival in the general ward, all the patients were once again
instructed on the use of the PCIA pump and VAS shortly,
and they were encouraged to push the PCIA button (self-
administer their own PCA medications) to achieve an res-
cue analgesic when their could not tolerance pain
throughout 48 h after operation.
Outcome measures and data collection
The study outcomes and the vital parameters were re-
corded at 2, 6, 12, 24, 36 and 48 h after arrival to the
ward. During the studied period, BP, HR and SpO2 were
monitored and were recorded at above time points.
Postoperative analgesia was used through the PCIA
pump over 48 h. Pain intensity was evaluated with VAS
at rest (VASR) and at coughing (VASC). VASR was
assessed with the patient lying supine and VASC was
assessed during change from coughing. The VAS scores
from zero (pain free) to 10 (maximum level of pain).
The restlessness scores was estimated based on Ramsay
sedation scale (RSS) from 1 to 6 (1 = anxious and agi-
tated, 2 = cooperative, tranquil, oriented, 3 = responds
only to verbal commands, 4 = asleep with brisk response
to light stimulation, 5 = asleep without response to light
stimulation, 6 = non responsive) [11]. Nausea and vomit-
ing (PONV) scores from 1 to 4 (1 = without nausea and
vomiting, 2 = nausea without vomiting, 3 = less than two
times vomiting, 4 = severe vomiting more than two
times) and satisfaction scored from 1 to 4 (1 = not satis-
fied, 2 =moderately satisfied, 3 = satisfied, 4 = very satis-
fied) [12, 13]. The patients were encouraged self-
administer their own PCIA medications to achieve an
rescue analgesic if the patient with pain scores more
than 3 at rest or during cough, the setting for PCIA was
one bolus with 10 min lockout. If patients required more
than three self-administer of rescue medications for pain
within 1 h, an adjuvant analgesic with IV injection me-
peridine 50 mg would be administered for insufficient
analgesia. The dosage of meperidine could be repeated
per 1 h and after each meperidine administration. The
number of PCIA self-administer and meperidine injec-
tion were recorded. Persistent nausea, vomiting, or prur-
itus would warrant PCIA termination with the patient
then being switched to an alternate analgesia modality.
Nausea and vomiting episodes were assessed at the same
intervals and recorded as present, with regard to the se-
vere PONV, when all patient were asked having degree
scores ≥ 3 at each time interval were counted. The drug-
related bradycardia (HR < 60 beats/min), hypotension
(>20% decrease in systolic blood pressure (SBP) or > 15%
decrease in diastolic blood pressure (DBP) from pre-
operative baseline), RSS≧3, and respiratory depression
(ventilatory frequency < 8 beats per minute (bpm) lasting
for more than 10 min) were considered as severe adverse
events. If severe adverse events occurred, the use of
PCIA was stopped temporarily and patient was observed
continuously for 30 min. If the adverse effects appear
more than 30 min or a further severe, the patient were
treated with appropriate medications. Hypotension or
bradycardia was treated with volume expansion, ephe-
drine, or atropine. Respiratory depression was treated
with naloxone and oxygen. Nausea and vomiting were
treated with metoclopramide. The presence of pruritus
was recorded and treated with diphenhydramine. Each
patient was asked to grade satisfaction (described above
from 1 to 4) with pain and sedation situation at the of
PCIA use.
Statistical analysis
To properly power this study, power analysis for testing
the hypothesis and determine sample size used a pri-
mary endpoint defined as sufentanil consumption at 48.
In the study literature. [6], the mean ± SD morphine
consumption for 48 h with and without dexmedetomi-
dine were 35 ± 28 and 54 ± 37 mg, respectively, a 41% re-
duction of morphine use with dexmedetomidine. In our
study, the hypothesis was that compared with control
group, dexmedetomidine group would achieve a 30% re-
duction of sufentanil consumption. A sample size of 25
patients was calculated using StatMate (ver.2.0; Graph-
Pad Software, San Diego, CA) to have at least 80% power
with α value of 0.05 significance level (two-tailed). Tak-
ing exclusion into account, we aimed to recruit 30 pa-
tients in each group.
Statistical analysis was performed using SPSS 13.0
(SPSS Inc., Chicago, USA). To compare patient charac-
teristics and operative data between the groups, inde-
pendent t-tests or Mann–Whitney U tests for
continuous variables, and Fischer exact tests or Chi-
square tests for categorical variable were performed. To
compare changes in VAS scores, Ramsay sedation
scores, and the PONV scores as well as hemodynamic
variables between the groups, a general linear model
used followed by two-way analysis of variance (ANOVA)
using post hoc testing for repeated measures. The cumu-
lative PCIA analgesic consumption and numbers of res-
cue analgesic were analyzed by Pair-simple tests as
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Fig. 1 Patients enrollment flow diagram. PCIA: patient-controlled intravenous analgesia
Table 1 Patient characteristics and intraoperative data. Values are mean ± SD, or number. All variable were similar between the two
groups
control group (n = 30) Dexmedetomidine group (n = 30) p
Age (years) 58 ± 8 56 ± 8 0.533
Weight (kg) 67 ± 7 68 ± 8 0.562
Height (cm) 167 ± 7 168 ± 7 0.551
Body mass index (kg.m2) 24 ± 1 24 ± 1 0.642
Sex (male/female) 4/16 15/15 0.796
ASA physical status (I/II) 5/25 2/28 0.421
Length of anesthesia (min) 137 ± 50 142 ± 47 0.638
Intraoperative sufentanil consumption (mcg) 70 ± 20 73 ± 24 0.535
Type of surgery (n)
Esophageal neoplasia resection 16 17 0.795
Lobectomy 6 7 0.754
Pneumonectomy 1 2 1.000
Mediastinal mass 2 2 NA
Pneumothorax 5 2 0.421
Extubated in operating room (number of patients) 21 1 0.584
Abbreaviations: SD, standard deviation; ASA, american society of anesthesiologists physical status
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appropriate. The differences in the proportions of PONV
severity and adverse events were analyzed by Fisher
exact tests or Chi-square tests as appropriate. Overall
satisfaction was compared between the groups using the
Kruskal-Wallis H test. All results were expressed with
95% confidence interval (CI), number of patients (%),
mean rank or odds ratio with 95% CI. A probability level
of < 0.05 was considered to be statistically significant.
Results
Sixty patients completed the study: 30 in each group, a
flowchart is shown in Fig. 1. There were no significant
differences between the groups regard to patient charac-
teristics and intra-operative variables (Table 1).
There was a significant difference in VASR and VASC
between the groups (P < 0.001). Individual intergroup
comparison at each time point are shown in Fig. 2. (a)
and (b). RSS scores was lower in the dexmedetomidine
group than in the control group (Fig. 3. (a). P < 0.035).
Pair-simple comparisons (mean) showed a lower
sufentanil consumption in the dexmedetomidine group
than in the control group at 48 h postoperatively (Fig. 4.
(a)). Total mean doses for each patient: 154 vs. 196 μg/
sufentanil, P = 0.034). Meperidine requirement were sta-
tistically different between the groups over time (Fig. 4.
(b). P = 0.002).
With regard to the PONV (Fig. 3. (b)), comparison of
the risk estimate by PONV scores ≥ 3, patients in the
dexmedetomidine group had a significantly reduced risk
Fig. 2 Postoperative visual analogue scale (VAS) pain scores.
Evaluation of pain score on VASR (a) and VASC (b) (Values represent
means with 95% confidence interval) in the two groups. P < 0.001 by
General Linear Model analysis, subsequent comparison between the
groups: asterisk = P < 0.023 in VASR and P < 0.02 in VASC after the
post hoc analyses, dexmedetomidine group vs. control group
Fig. 3 Postoperative Ramsay sedation scale (RSS). (a) restlessness
scores and PONV scores. (b) Evaluation of RSS and PONV scores
(Values represent mean with 95% confidence interval) in the two
groups. P < 0.001 by General Linear Model analysis, subsequent
comparison between the groups: asterisk = P < 0.05 after the post
hoc analyses, dexmedetomidine group vs. control group. PONV,
postoperative nausea and vomiting
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of PONV during the 6 to 48 h compared with control
group (odds ratio 0.184, 95% CI 0.09 to 0.38; P < 0.001),
and the incidences of PONV between the groups during
48 h was comparable (12% vs 33%). No difference was
found in the occurrence of other complications, such
as haemodynamic or respiratory. No life-threatening
complication related to the use of the two protocol
occurred (Table 2). Although there are statistically
differences in HR or BP values at some time points
(Fig. 5. (a) and (b)), there was a non-significant trend
for a lower HR and BP in the dexmedetomidine
group vs. Control. Accordingly, the overall postopera-
tive satisfaction rating for 48 h were different between
the two groups (n = 180, Mean Rank was 146.3 vs
214.7, x2 = 41.8, df = 1, P = 0.000) (Fig. 6).
Discussion
We have demonstrated that intense postoperative pain
after thoracotomy can be treated successfully with a
lower dose continuous infusion of combining dexmede-
tomidine with sufentanil in PCIA. The combination of
dexmedetomidine and sufentanil allowed a significant
reduction in sufentanil consumption, supplemental anal-
gesic requirements and decreased incidence of nausea or
vomiting, and to maintain a good hemodynamic
stability.
Increased levels of safety and efficacy of PCIA protocol
are desirable for patients who have undergoing a major
thoracotomy, while protecting the pulmonary function
and promotes patient well-being. However, a numberous
strategies have been designed to reduce postoperative
pain for various surgery, and dexmedetomidine as an ad-
junct combining with an opioid in PCIA for pain man-
agements has been reported to be associated with
maximizing pain relief and minimizing analgesic-related
side-effects [5]. From the clinical viewpoint, however,
the drug doses for patients can be calculated simply on
per kg basis is importance (except for obese patients).
The recommended infusion dose of dexmedetomidine is
0.2 to 0.7 μg.kg−1.h−1 for a major abdominal surgery in
adults, and showed a reduction in ‘rescue’ opioid con-
sumption in the first 24 h after surgery, together with in
general no clinically important differences in postopera-
tive pain when compared with placebo [14]. In addition,
a similar results were found in the context of thoracic
surgery, an infusion dose of 0.04 μg.kg−1.h−1 dexmedeto-
midine combining with 0.02 μg.kg−1.h−1 sufentanil re-
duced postoperative pain and greater patient satisfaction
Fig. 4 Cumulative PCIA sufentanil consumption and supplementary
meperidine doses. (a) There is significantly differences in cumulative
PCIA sufentanil consumption at 48 h between in the control group
and the dexmedetomidine group (Values represent means with 95%
confidence interval, cumulative dose at 48 h for 196.6 ± 22.2 vs.
154.3 ± 17.5 μg, P = 0.034). Sufentanil consumption in the
dexmedetomidine group was required 22% less than the control
group. (b) Cumulative of meperidine supplementary doses at each
time intervals after surgery was significantly lesser in the
dexmedetomidine gourp than the control group (P = 0.002). PCIA,
patient-controlled intravenous analgesia; SD, standard deviation







Postoperative complications, No %
Hypotension 0 (0) 2 (6.7) 0.472
Hypertension 7 (23.3) 4 (13.3) 0.505
Bradycardia 2 (6.7) 7 (23.3) 0.148
Respiration
despression
9 (30.0) 4 (13.3) 0.117
Hypoxemia 6 (20.0) 142 ± 47 1.000
Excessive
sedation
2 (6.7) 73 ± 24 0.083
Pruritus 7 (23.3) 2 (6.7) 0.147
Note: Hypotension, hypertension, bradycardia, respiration depression,
hypoxemia and excessive sedation were defined as mean blood pressure <
60 mmHg, or > 90 mmHg, heart rate < 60 beat per minute, respiratory rate < 8
beat per minute, pulse oxygen saturation < 93%, and Ramsay sedation scale ≥
3 at least once during postopeartive 48 h, respectively. No, number
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without other clinically relevant side effect for highly
nicotine-dependence patients during the initial 72 h after
surgery [15, 16]. We selected a maintenance infusion of
0.064 μg.kg−1.h−1, the maintenance time of dexmedeto-
midine consumed in conjunction with sufentanil via
PCIA was 48 h of post-thoracotomy analgesic, which al-
most is negligible among the lowest limit used for sed-
ation within the ranges of the recommended infusion.
This may explain why receiving dexmedetomidine re-
quired 22% less PCIA sufentani compared with sufenta-
nil alone, such as analgesic and sedation, are affected
differently by dexmedetomidine doses [17]. while we
have also found that beneficial influence on optimal bal-
ance between postoperative pain and side effects with
the time period when cumulative sufentanil consump-
tion was significantly lower in the dexmedetomidine
group. Obviously, these advantages shown by the regime
is very important for thoracic surgery during the initial
two day with a consequent decrease in lung volumes
and capacities due to the pain response [18].
The sedation measures scores in the dexmedetomidine
group were significantly better than the control group at
all time points; however, sedation and analgesia probably
account for the opioid-sparing effects of this class of
Fig. 5 Postoperative hemodynamic variables was assessed at 2, 6, 12, 24, 36 and 48 h postoperatively (Values represent means with 95%
confidence interval). Although the heart rate (a), systolic pressure and diastolic pressure (b) were compared between the groups postoperatively.
asterisk = P < 0.05 by the post hoc analyses after a General Linear Model, dexmedetomidine group vs. control group
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compound [19]. We suggest that some more serious
complications such as PONV and wound dehiscence in
the postoperative context after major elective surgery
might be benefited by the use of dexmedetomidine due
to an appropriate sedative effect [20, 21]. For these pa-
tients, an opioid-based PCIA regimen may also provide
additional physiological benefits by a multimodal ap-
proach that exert opioid-sparing effect as a feasible op-
tion. However, sufentanil, although induces side effects
characteristic of all opioids, even advanced sedation
levels precede respiratory depression, it remain attrib-
uted to excessive dosing as a factor [22, 23]. A wider
therapeutic index in sufentanil has been demonstrated
compared with other commonly used opioids for PCIA,
and sufentanil is not processed into active metabolites
[24, 25]. Also, the optimal dose of dexmedetomidine
combining with sufentanil is vital and clinically the anal-
gesic and sedation is satisfied maximumly, and the con-
sumption of sufentanil is reported to be reduced when
administered together with dexmedetomidine [26]. A re-
cent study in vivo have showed that a lower loading dose
of dexmedetomidine (<10 μg/kg) prevent response to
noxious stimulation mainly via enhanced inhibitory post-
synaptic transmission within the superficial dorsal horn
without altering excitatory synaptic transmission or
evoking direct postsynaptic membrane currents. In
contrast, higher doses of dexmedetomidine (>10 μg/
kg) induced outward currents by a direct postsynaptic
action [27]. Therefore, experimental data suggest dex-
medetomidine synergistic analgesic interactions with
opioids on the cortex at low concentrations, which is
consistent with our observation at the concentration
range of opioid-sparing effects. A strong linear
relation between an area under the dexmedetomidine
concentration-time curve and a cumulative dexmede-
tomidine dose has been demonstrated in critically ill
patients [28]. This has led to the hypothesis that
opioid-sparing effects of dexmedetomidine was pro-
duced by inhibits pain transmission with a concentra-
tion dependent in the peripheral and central.
The other most important to understand what was in-
duced through pain response for the interpretation of
our result. Because of the major surgical procedure and
long anaesthesia are also main sources of stress to pa-
tients. During surgery, the suppression of inflammation
to painful stimuli is an important component of anal-
gesia. Tissue injury are able to stimulate the release of
cytokines and chemokines in cell signaling events under-
lying inflammation, and excessive release of cytokines
and chemokines has been reported to be associated with
pain associated with tissue injury. Several studies in hu-
man have shown that the excessive activation of the
sympathetic nervous system and inflammation were alle-
viated by central sympatholytic effects of dexmedetomi-
dine during the cytokine secretion secondary to immune
system interactions [29, 30]. Therefore, the likely in-
volvement of the inhibition of nuclear factor kappa-β ac-
tivation in the mechanism of dexmedetomidine action
suggeats that the nuclear factor kappa-β receptor antag-
onists may beneficially inhibit inflammatory responses
associated with organ injury and acute or chronic pain
conditions [31].
Our study has some limitation. First, there are limited
large sample data on perioperative outcome comparisons
of patients undergoing thoracotomy procedure who had
either a opioids or dexmedetomidine as an aduvants in
PCIA for postoperative pain management. Second, dex-
medetomidine was administered at a alone individual in-
fusion rate of 0.064 μg.kg−1.h−1 for postoperative
analgesia. We did not measure the serum concentration
of dexmedetomidine in this study at any time point.
Third, we only had investigated middle-aged adults pa-
tients after thoracic surgery, so it remains to be proven
whether our finding are also applicable to young and
elderly adults patients after thoracic surgery or patients
undergoing other types of surgery. Finally, this study was
performed at a single center. Investigation of more di-
verse populations from different center and using vari-
ous techniques would furnish more conclusive results.
Again, despite the potential benefit of dexmedetomidine
include a significant opioid-sparing effects for PCIA, it is
not labelled for such use so a current use is not recom-
mendable yet.
Conclusions
Our results show the benefit of dexmedetomidine
(0.064 μg.kg−1.h−1) combined with sufentanil (0.048 μg.kg
Fig. 6 Patients’ overall postoperative satisfaction rating with 48 h
(control group vs dexmedetomidine group). The satisfaction score was
assessed using a 4-point scale (not satisfied, moderately satisfied, satisfied,
very satisfied). The four categories (N= 180, Mean Rank was 146.3 vs
214.7, x2 = 41.8, df= 1, P= 0.000)
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−1.h−1) in PCIA regarding post-thoracotomy pain and
sufentanil requirements, and more particularly in greater
overall patient satisfaction by a appropriate sedation and
reduced the incidence of nausea or vomiting with PCIA.
These finding are in agreement with those of the litera-
ture, and more studies are still required to determine the
optimal dose of dexmedetomidine for reducing postopera-
tive pain and sufentanil requirements in young or elderly
adult patients after thoracic surgery.
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